Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Constipation Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025

Table of Content

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Constipation Treatment Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Market Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunities
     4.5. Constipation Treatment Market Analysis and Forecast, 2017 – 2025
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s five forces analysis
     4.7. Global Prevalence of Chronic Constipation
     4.8. Global Prevalence if Irritable Bowel Syndrome
     4.9. Pipeline Analysis
     4.10. Value Chain Analysis
     4.11. Market Outlook

5. Global Constipation Treatment Market Analysis and Forecasts, By Therapeutic Option
     5.1. Introduction & Definition
     5.2. Key Findings
     5.3. Key Trends
     5.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
            5.4.1. Laxatives
                       5.4.1.1. Bulk forming agents
                       5.4.1.2. Osmotic laxatives
                       5.4.1.3. Stimulant laxatives
                       5.4.1.4. Others
            5.4.2. Chloride channel activators
            5.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            5.4.4. GC-C Agonists
            5.4.5. 5-HT4 Receptor Agonists
     5.5. New Chronic Constipation Therapies Market Revenue (US$) Forecast, 2017-2025
     5.6. Market Attractiveness, By Therapeutic Option

6. Global Constipation Treatment Market Analysis and Forecasts, By Disease Type
     6.1. Introduction & Definition
     6.2. Key Findings 
     6.3. Key Trends
     6.4. Market Size (US$ Mn) Forecast, By Disease Type
            6.4.1. Chronic idiopathic constipation (CIC)
            6.4.2. Irritable bowel syndrome with constipation (IBS-C)
            6.4.3. Opioid-induced constipation (OIC)
     6.5. Market Attractiveness, By Disease Type

7. Global Constipation Treatment Market Analysis and Forecasts, By Distribution Channel
     7.1. Introduction & Definition
     7.2. Key Findings 
     7.3. Key Trends
     7.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
            7.4.1. Hospital Pharmacies
            7.4.2. Retail Pharmacies
            7.4.3. Online Pharmacies
     7.5. Market Attractiveness, By Distribution Channel

8. Global Constipation Treatment Market Analysis and Forecasts, By Region
     8.1. Introduction & Definition
     8.2. Key Findings 
     8.3. Key Trends
     8.4. Market Size (US$ Mn) Forecast, By Region
            8.4.1. North America
            8.4.2. Europe
            8.4.3. Asia Pacific
            8.4.4. Latin America
            8.4.5. Middle East and Africa
            8.4.6. Commonwealth of Independent States
     8.5. Market Attractiveness, By Region

9. North America Constipation Treatment Market Analysis and Forecast
     9.1. Introduction
     9.2. Key Findings 
     9.3. Key Trends
     9.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
            9.4.1. Laxatives
                       9.4.1.1. Bulk forming agents
                       9.4.1.2. Osmotic laxatives
                       9.4.1.3. Stimulant laxatives
                       9.4.1.4. Others
            9.4.2. Chloride channel activators
            9.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            9.4.4. GC-C Agonists
     9.5. Market Size (US$ Mn) Forecast, By Disease Type
            9.5.1. Chronic idiopathic constipation (CIC)
            9.5.2. Irritable bowel syndrome with constipation (IBS-C)
            9.5.3. Opioid-induced constipation (OIC)
     9.6. Market Size (US$ Mn) Forecast, By Distribution Chanel
            9.6.1. Hospital Pharmacies
            9.6.2. Retail Pharmacies
            9.6.3. Online Pharmacies
     9.7. Market Size by Value (US$ Mn) Forecast, By Country
            9.7.1. The U.S.
            9.7.2. Canada
     9.8. Market Attractiveness Analysis 
            9.8.1. By Therapeutic Option
            9.8.2. By Disease Type
            9.8.3. By Distribution Channel
            9.8.4. By Country

10.  Europe Constipation Treatment Market Analysis and Forecast
     10.1. Introduction
     10.2. Key Findings 
     10.3. Key Trends
     10.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
            10.4.1. Laxatives
                       10.4.1.1. Bulk forming agents
                       10.4.1.2. Osmotic laxatives
                       10.4.1.3. Stimulant laxatives
                       10.4.1.4. Others
            10.4.2. Chloride channel activators
            10.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            10.4.4. GC-C Agonists
            10.4.5. 5-HT4 Receptor Agonists
     10.5. Market Size (US$ Mn) Forecast, By Disease Type
            10.5.1. Chronic idiopathic constipation (CIC)
            10.5.2. Irritable bowel syndrome with constipation (IBS-C)
            10.5.3. Opioid-induced constipation (OIC)
     10.6. Market Size (US$ Mn) Forecast, By Distribution Chanel
            10.6.1. Hospital Pharmacies
            10.6.2. Retail Pharmacies
            10.6.3. Online Pharmacies
     10.7. Market Size by Value (US$ Mn) Forecast, By Country
            10.7.1. Germany
            10.7.2. France
            10.7.3. U.K.
            10.7.4. Spain
            10.7.5. Italy
            10.7.6. Rest of Europe
     10.8. Market Attractiveness Analysis 
            10.8.1. By Therapeutic Option
            10.8.2. By Disease Type
            10.8.3. By Distribution Channel
            10.8.4. By Country

11.  Asia Pacific Constipation Treatment Market Analysis and Forecast
     11.1. Introduction
     11.2. Key Findings 
     11.3. Regulatory Scenario 
     11.4. Key Trends
     11.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
            11.5.1. Laxatives
                       11.5.1.1. Bulk forming agents
                       11.5.1.2. Osmotic laxatives
                       11.5.1.3. Stimulant laxatives
                       11.5.1.4. Others
            11.5.2. Chloride channel activators
            11.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            11.5.4. GC-C Agonists
            11.5.5. 5-HT4 Receptor Agonists
     11.6. Market Size (US$ Mn) Forecast, By Disease Type
            11.6.1. Chronic idiopathic constipation (CIC)
            11.6.2. Irritable bowel syndrome with constipation (IBS-C)
            11.6.3. Opioid-induced constipation (OIC)
     11.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
            11.7.1. Hospital Pharmacies
            11.7.2. Retail Pharmacies
            11.7.3. Online Pharmacies
     11.8. Market Size by Value (US$ Mn) Forecast, By Country
            11.8.1. Philippines
            11.8.2. Thailand
            11.8.3. Indonesia
            11.8.4. South Korea
            11.8.5. Singapore
            11.8.6. Malaysia
            11.8.7. Rest of Asia Pacific
     11.9. Market Attractiveness Analysis 
            11.9.1. By Therapeutic Option
            11.9.2. By Disease Type
            11.9.3. By Distribution Channel
            11.9.4. By Country

12.  Latin America Constipation Treatment Market Analysis and Forecast
     12.1. Introduction
     12.2. Key Findings 
     12.3. Regulatory Scenario 
     12.4. Key Trends
     12.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
            12.5.1. Laxatives
                       12.5.1.1. Bulk forming agents
                       12.5.1.2. Osmotic laxatives
                       12.5.1.3. Stimulant laxatives
                       12.5.1.4. Others
            12.5.2. Chloride channel activators
            12.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            12.5.4. GC-C Agonists
            12.5.5. 5-HT4 Receptor Agonists
     12.6. Market Size (US$ Mn) Forecast, By Disease Type
            12.6.1. Chronic idiopathic constipation (CIC)
            12.6.2. Irritable bowel syndrome with constipation (IBS-C)
            12.6.3. Opioid-induced constipation (OIC)
     12.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
            12.7.1. Hospital Pharmacies
            12.7.2. Retail Pharmacies
            12.7.3. Online Pharmacies
     12.8. Market Size by Value (US$ Mn) Forecast, By Country
            12.8.1. Brazil
            12.8.2. Mexico
            12.8.3. Argentina
            12.8.4. Ecuador
            12.8.5. Peru
            12.8.6. Rest of Latin America
     12.9. Market Attractiveness Analysis 
            12.9.1. By Therapeutic Option
            12.9.2. By Disease Type
            12.9.3. By Distribution Channel
            12.9.4. By Country

13.  Middle East and Africa Constipation Treatment Market Analysis and Forecast
     13.1. Introduction
     13.2. Key Findings 
     13.3. Regulatory Scenario      
     13.4. Key Trends
     13.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
            13.5.1. Laxatives
                       13.5.1.1. Bulk forming agents
                       13.5.1.2. Osmotic laxatives
                       13.5.1.3. Stimulant laxatives
                       13.5.1.4. Others
            13.5.2. Chloride channel activators
            13.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            13.5.4. GC-C Agonists
            13.5.5. 5-HT4 Receptor Agonists
     13.6. Market Size (US$ Mn) Forecast, By Disease Type
            13.6.1. Chronic idiopathic constipation (CIC)
            13.6.2. Irritable bowel syndrome with constipation (IBS-C)
            13.6.3. Opioid-induced constipation (OIC)
     13.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
            13.7.1. Hospital Pharmacies
            13.7.2. Retail Pharmacies
            13.7.3. Online Pharmacies
     13.8. Market Size by Value (US$ Mn) Forecast, By Country
            13.8.1. Saudi Arabia
            13.8.2. South Africa
            13.8.3. Rest of Middle East and Africa
     13.9. Market Attractiveness Analysis 
            13.9.1. By Therapeutic Option
            13.9.2. By Disease Type
            13.9.3. By Distribution Channel
            13.9.4. By Country

14.  Commonwealth of Independent States Constipation Treatment Market Analysis and Forecast
     14.1. Introduction
     14.2. Key Findings 
     14.3. Market Size (US$ Mn) Forecast, By Therapeutic Option
            14.3.1. Laxatives
                       14.3.1.1. Bulk forming agents
                       14.3.1.2. Osmotic laxatives
                       14.3.1.3. Stimulant laxatives
                       14.3.1.4. Others
            14.3.2. Chloride channel activators
            14.3.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            14.3.4. GC-C Agonists
            14.3.5. 5-HT4 Receptor Agonists
     14.4. Market Size (US$ Mn) Forecast, By Disease Type
            14.4.1. Chronic idiopathic constipation (CIC)
            14.4.2. Irritable bowel syndrome with constipation (IBS-C)
            14.4.3. Opioid-induced constipation (OIC)
     14.5. Market Size (US$ Mn) Forecast, By Distribution Chanel
            14.5.1. Hospital Pharmacies
            14.5.2. Retail Pharmacies
            14.5.3. Online Pharmacies
     14.6. Market Size by Value (US$ Mn) Forecast, By Country
            14.6.1. Russian Federation
            14.6.2. Ukraine
            14.6.3. Kazakhstan
     14.7. Market Attractiveness Analysis 
            14.7.1. By Therapeutic Option
            14.7.2. By Disease Type
            14.7.3. By Distribution Channel
            14.7.4. By Country

15.  Competition Landscape
     15.1. Market Player – Competition Matrix (By Tier and Size of companies)
     15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            15.2.1. Takeda Pharmaceutical Company Ltd
                       15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.1.2. Product Portfolio
                       15.2.1.3. SWOT Analysis
                       15.2.1.4. Financial Overview
                       15.2.1.5. Strategic Overview
            15.2.2. Synergy Pharmaceuticals, Inc.
                       15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.2.2. Product Portfolio
                       15.2.2.3. SWOT Analysis
                       15.2.2.4. Financial Overview
                       15.2.2.5. Strategic Overview
            15.2.3. Sucampo Pharmaceuticals, Inc.
                       15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.3.2. Product Portfolio
                       15.2.3.3. SWOT Analysis
                       15.2.3.4. Financial Overview
                       15.2.3.5. Strategic Overview
            15.2.4. Ironwood Pharmaceuticals, Inc.
                       15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.4.2. Product Portfolio
                       15.2.4.3. SWOT Analysis
                       15.2.4.4. Financial Overview
                       15.2.4.5. Strategic Overview
            15.2.5. Valeant Pharmaceuticals International, Inc.
                       15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.5.2. Product Portfolio
                       15.2.5.3. SWOT Analysis
                       15.2.5.4. Financial Overview
                       15.2.5.5. Strategic Overview
            15.2.6. Abbott Laboratories
                       15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.6.2. Product Portfolio
                       15.2.6.3. SWOT Analysis
                       15.2.6.4. Financial Overview
                       15.2.6.5. Strategic Overview
            15.2.7. AstraZeneca
                       15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.7.2. Product Portfolio
                       15.2.7.3. SWOT Analysis
                       15.2.7.4. Financial Overview
                       15.2.7.5. Strategic Overview
            15.2.8. Cosmo Pharmaceuticals NV
                       15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.8.2. Product Portfolio
                       15.2.8.3. SWOT Analysis
                       15.2.8.4. Financial Overview
                       15.2.8.5. Strategic Overview
            15.2.9. Sanofi
                       15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.9.2. Product Portfolio
                       15.2.9.3. SWOT Analysis
                       15.2.9.4. Financial Overview
                       15.2.9.5. Strategic Overview
            15.2.10. Daewoong Pharmaceuticals Co. Ltd.
                       15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.10.2. Product Portfolio
                       15.2.10.3. SWOT Analysis
                       15.2.10.4. Financial Overview
                       15.2.10.5. Strategic Overview
            15.2.11. Bayer AG
                       15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.11.2. Product Portfolio
                       15.2.11.3. SWOT Analysis
                       15.2.11.4. Financial Overview
                       15.2.11.5. Strategic Overview
            15.2.12. Prestige Brands Holdings, Inc.
                       15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.12.2. Product Portfolio
                       15.2.12.3. SWOT Analysis
                       15.2.12.4. Financial Overview
                       15.2.12.5. Strategic Overview
            15.2.13. Janssen Pharmaceutical Company
                       15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.13.2. Product Portfolio
                       15.2.13.3. SWOT Analysis
                       15.2.13.4. Financial Overview
                       15.2.13.5. Strategic Overview
            15.2.14. Shionogi & Co., Ltd.
                       15.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.14.2. Product Portfolio
                       15.2.14.3. SWOT Analysis
                       15.2.14.4. Financial Overview
                       15.2.14.5. Strategic Overview
            15.2.15. Albireo Pharma, Inc.
                       15.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.15.2. Product Portfolio
                       15.2.15.3. SWOT Analysis
                       15.2.15.4. Financial Overview
                       15.2.15.5. Strategic Overview
            15.2.16. Renexxion, LLC
                       15.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.16.2. Product Portfolio
                       15.2.16.3. SWOT Analysis
                       15.2.16.4. Strategic Overview

16. Key Takeaways

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote